HB 1034
In CommitteeHouse
Nonopioid drugs for pain
Concerning nonopioid drugs for the treatment of pain.
This status may be delayed. See Action History below for the latest updates.
How does a bill become law?
- Introduced: The bill is filed and assigned a number.
- Committee: A subject-matter committee holds hearings, takes public testimony, and decides whether to advance the bill.
- Floor Vote: The full chamber (House or Senate) debates and votes on the bill.
- Opposite Chamber: The bill repeats the committee and floor vote process in the other chamber.
- Governor: The Governor reviews the bill and decides whether to sign or veto it.
- Signed: The bill has been signed into law.
AI Analysis
This bill ensures that nonopioid pain medications—like acetaminophen, NSAIDs, or physical therapy—are covered more fairly than opioids by health plans. It prevents insurers from making it harder or more expensive to get these safer alternatives. Starting January 1, 2026, health plans must treat nonopioid drugs at least as favorably as opioids in terms of coverage rules.
- Bars health plans (including state employee plans, private insurance, and Medicaid managed care) from designating nonopioid pain drugs as 'nonpreferred' if any opioid drug is 'preferred'.
- Prohibits health plans from imposing stricter coverage rules—such as prior authorization or step therapy—on nonopioid pain drugs compared to opioids.
- Requires the Department of Health to create and post an educational pamphlet by January 1, 2026, explaining nonopioid pain treatment options, including medications and non-drug therapies.
- Defines 'nonopioid drug' as an FDA-approved drug or biological product that relieves pain without acting on opioid receptors.
- Amends existing definitions in RCW 48.43.400 to clarify terms like 'step therapy protocol' and 'prior authorization' used in the new rules.
Who is affected
- State employees and their dependents — Employees and dependents covered under state-sponsored health plans (e.g., Washington State Health Benefit Exchange plans, state employee plans) will have better access to nonopioid pain treatments, as insurers will no longer be allowed to impose stricter coverage rules on these drugs compared to opioids.
- Private health plan members — Residents enrolled in private health insurance plans (including individual, small group, and large group plans) issued or renewed on or after January 1, 2026, will see more equitable coverage for nonopioid pain medications, with fewer barriers like prior authorization or step therapy requirements.
- Medicaid (Apple Health) enrollees — Medicaid (Apple Health) enrollees served through managed care organizations will benefit from improved access to nonopioid pain treatments, as MCOs must follow the same coverage equity rules as other health plans.
- Patients managing pain — People with chronic or acute pain—especially those at risk of opioid dependence or who have had negative experiences with opioids—may benefit from earlier access to safer, nonaddictive alternatives.
Pro/Con Analysis
Stronger case for benefits
Potential Benefits (5)
Prevents insurers from placing nonopioid pain medications (e.g., acetaminophen, ibuprofen, gabapentin, physical therapy) on nonpreferred tiers when opioids are preferred—directly improving access to safer alternatives for patients who may be at risk of opioid misuse or dependence.
HealthcarePeopleRef: Sec. 1(1)(a), Sec. 2(1)(a), Sec. 3(1)(a)Bars step therapy and prior authorization requirements for nonopioids that are stricter than those for opioids—reducing administrative barriers that delay access to nonaddictive pain relief, especially for patients with chronic pain or prior negative opioid experiences.
HealthcarePeopleRef: Sec. 1(1)(b), Sec. 2(1)(b), Sec. 3(1)(b)Mandates a publicly available educational pamphlet on nonopioid alternatives, increasing patient and provider awareness of safer pain management options—potentially shifting clinical norms away from overreliance on opioids.
HealthcarePeopleRef: Sec. 4May reduce long-term public health expenditures by decreasing opioid-related harms (e.g., addiction treatment, emergency department visits, overdose deaths), which disproportionately burden Medicaid and public health systems.
HealthcarePeopleRef: Fiscal Impact sectionApplies uniformly across state employee plans, private insurance, and Medicaid (Apple Health), ensuring equitable access to nonopioid pain treatments for low-income, elderly, and working Washingtonians alike—reducing disparities in pain management access.
HealthcarePeopleRef: Sec. 1–3 (entire bill)
Potential Concerns (5)
Health plans may respond to the mandate by broadening step therapy or prior authorization requirements across *all* pain medications (including opioids) to avoid violating the rule, potentially increasing administrative burden and delays for all pain treatments—not just nonopioids.
HealthcareRef: Sec. 1(1)(b), Sec. 2(1)(b), Sec. 3(1)(b)The educational pamphlet may have limited real-world impact if patients cannot act on it due to provider inertia, lack of training in nonopioid pain management, or insufficient time in clinical visits—especially in rural or under-resourced areas.
HealthcareRef: Sec. 4Health plans and PBMs may incur increased administrative costs to redesign formularies and utilization management protocols, which could be passed on to employers or consumers through higher premiums—though the fiscal impact is unspecified.
Business & EmploymentRef: Sec. 1–3The bill does not address formulary access or out-of-pocket cost disparities—insurers could still cover nonopioids but place them on high-tier formularies with high copays, undermining the intent if cost-sharing is not regulated.
HealthcareRef: Sec. 1–3The prohibition on “more restrictive” utilization management applies only *relative* to opioids—not to a neutral standard—so if opioids are already heavily restricted, nonopioids may remain comparably restricted, limiting real-world access improvements.
HealthcareRef: Sec. 1–3
Who Is Most Affected
Low- and middle-income patients with chronic pain—especially those on Medicaid or exchange plans—will benefit most, as they face higher barriers to accessing nonopioid care and are at greater risk of opioid harm. The bill directly improves their ability to access safer, preferred treatments without extra hurdles.
Primary care and pain management providers will gain clinical flexibility to treat patients with nonopioid options first-line, but may face administrative adjustments to comply with new coverage rules. Overall, this supports evidence-based, patient-centered care.
Pharmaceutical manufacturers of nonopioid analgesics (e.g., generic NSAIDs, acetaminophen, gabapentin) stand to gain increased demand and formulary placement, but since these are low-cost generics, the financial benefit is modest and broadly distributed—not concentrated in big pharma.
Health plans and PBMs will need to revise formulary and utilization management protocols, incurring administrative costs. However, since the mandate applies equally to all plans and does not require new spending, the net fiscal impact is likely neutral to slightly negative for them.
Employers offering self-funded plans may see modest premium savings over time due to reduced opioid-related complications, but the effect will be small and delayed. Most employers will be unaffected in the short term, as the rule applies only to plans issued/renewed after Jan 1, 2026.